MedTrace Logo

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

NCT05655949 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-22

No results posted yet for this study

Summary

This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery.

The specific names of the interventions that will be used are:

* Y-90 (a type of radiation microsphere bead)
* Durvalumab (a type of immunotherapy)
* Gemcitabine (a type of chemotherapy)
* Cisplatin (a type of chemotherapy)

Conditions

Interventions

DRUG

Gemcitabine

Intravenous infusion

DRUG

Cisplatin

Intravenous infusion

DRUG

Durvalumab

Intravenous infusion

RADIATION

Yttrium-90

Injection of radiation microsphere beads

Sponsors & Collaborators

Principal Investigators

  • Andrea Bullock, MD, MPH · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-13
Primary Completion
2026-12-01
Completion
2027-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05655949 on ClinicalTrials.gov